Regulations.gov document
Exhibit 3- Pharmacokinetic Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients…
Supporting & Related Material · FDA-2019-P-4832 · posted Oct 17, 2019
Key facts
| Document ID | FDA-2019-P-4832-0005 |
|---|---|
| Title | Exhibit 3- Pharmacokinetic Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients With Epilepsy Under Ictal and Inter-ictal Conditions – Interim Report re: Citizen Petition from Arent Fox LLP on behalf of Aquestive Therapeutics, Inc. |
| Document type | Supporting & Related Material |
| Agency | FDA |
| Docket | FDA-2019-P-4832 |
| Posted | Oct 17, 2019 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: